Drug companion protocol
5-Amino-1MQ
A small-molecule NNMT inhibitor studied in metabolic and NAD+ biology, mostly in preclinical and early research settings.
Quickstart Highlights
- Drug class
- NNMT inhibitor
- Route
- Subcutaneous injection
- Schedule
- Editorial research protocol reference describes daily subcutaneous use from a 10 mg vial; no approved human dosing label exists
- Evidence score
- 25
Quickstart highlights
- 💉Subcutaneous injection
- 🔬NNMT inhibitor
- 🧪Lyophilised powder — requires reconstitution with bacteriostatic water
How this works
Mechanism of action and pharmacokinetic profile from published data.
5-Amino-1MQ is a cell-permeable nicotinamide N-methyltransferase (NNMT) inhibitor. Research interest centers on nicotinamide conservation, NAD+ availability, SIRT1-linked metabolic pathways, and adipose-tissue metabolism.
Half-life
5.3 h
- Time to peak (Tmax)
- Not established in an approved label.
- Clearance
- Not characterised in an approved human prescribing label.
- Elimination half-life
- One editorial source cites approximately 3.8-6.9 hours from pharmacokinetic research; this is not an approved dosing-label parameter.
- Bioavailability
- Editorial protocol pages discuss subcutaneous administration; human therapeutic bioavailability is not established.
Dosing & Reconstitution Guide
Full preparation, protocol, and administration reference for compounded lyophilised formulations.
Protocol overview
Editorial research protocol reference describes daily subcutaneous use from a 10 mg vial; no approved human dosing label exists.
Dose escalation phases
Editorial 5-Amino-1MQ 10 mg vial reference
| Phase | Dose | Frequency | Guidance |
|---|---|---|---|
| Days 1-2 tolerance Week 1-1 | 2.5 mg | once daily | Editorial tolerance reference. Not approved dosing. Do not treat as a prescribing protocol. |
| Days 3+ standard Week 1+ | 5 mg | once daily or split BID | Editorial standard reference. No approved escalation or maintenance schedule exists. |
Supplies needed
- ◦Research vial and diluent — Use the vial size and bacteriostatic water volume described by the applicable research protocol or compounder.
Editorial 10 mg vial protocol (5 mg/mL)
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| Days 1-2 tolerance reference | 50 | 0.50 |
| Days 3+ standard reference | 100 | 1.00 |
| Alternative BID reference, per injection | 50 | 0.50 |
Reconstitution steps
Vial size
10 mg
BAC water to add
2 mL
Resulting concentration
5 mg/mL
At 5 mg/mL, 1 U-100 unit = 0.01 mL = 0.05 mg (50 mcg).
Editorial protocol: allow vial to reach room temperature, add bacteriostatic water slowly down the vial wall, avoid foaming, gently swirl or roll until clear, label, protect from light, and refrigerate.
Injection steps
- 1Reconstitute gently
Allow the vial to reach room temperature, add diluent slowly down the vial wall, gently swirl or roll until clear, and label with date and concentration.
Storage instructions
Before reconstitution
Editorial protocol describes frozen lyophilized storage around -20 C.
After reconstitution
Refrigerate reconstituted solution at 2-8 C and protect from light.
Editorial page describes 2-4 weeks.
Important notes
- !Research protocol limitation
This injection guide supports structured API display only and is not a prescribing protocol.
Concentration calculations are standard compounding arithmetic. Protocol phases are drawn from published Phase 2 trial data. Your prescriber and dispensing pharmacy determine the actual dose, vial size, and escalation schedule for your treatment.
Your journey
Where you are in a typical protocol, and what one dose cycle looks like. Educational — your prescriber tailors the plan to you.
Protocol timeline
Tolerance reference
Weeks 1–12.5 mgevery 1dWhat to expect: editorial low-start reference
Focus on: track tolerance, site rotation, avoid self-escalation
Common adjustments: no approved hold or reduction rule exists
Standard reference
Weeks 1+5 mgevery 1dWhat to expect: editorial daily or BID reference
Focus on: track adverse symptoms, maintain sterile handling
Common adjustments: no approved maintenance rule exists
Daily companion
Practical playbooks for managing symptoms, eating around side effects, tracking what matters, and reporting back to your clinician.
Food guidance by situation
Prefer: protein-forward meals, steady hydration
Limit: excess stimulants
Avoid: unsupported protocol stacking
The source discusses metabolic research context; nutrition copy should stay general and non-prescriptive.
What to track
Suggested check-in cadence: daily.
Injection-site reaction
scale 0 10
Energy
scale 0 10
Sleep quality
scale 0 10
Unexpected symptoms
text
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Red-flag symptoms — seek urgent care
- Unexpected systemic reactionUrgent careSeek urgent care for breathing symptoms, swelling, chest symptoms, severe dizziness, or rapidly worsening reaction after 5-Amino-1MQ.
- Unexpected systemic reaction. Stop use and seek medical advice for rash, swelling, breathing symptoms, chest symptoms, severe dizziness, or any concerning reaction after an unapproved injectable product.
Structured warnings
Long-term human safety not established
5-Amino-1MQ has no approved human therapeutic dosing label. Human safety, dose adjustment, and monitoring standards are not established.
Unexpected systemic reaction
Stop use and seek medical advice for rash, swelling, breathing symptoms, chest symptoms, severe dizziness, or any concerning reaction after an unapproved injectable product.
Indication and approval status
No approved therapeutic indication represented in this catalogue entry.
No approved prescribing population.
Who should not take this
5-Amino-1MQ is not approved by major regulators for human therapeutic use. No formal contraindications, dose adjustments, or monitoring requirements exist from an approved prescribing label.
Missed-dose guidance
No approved missed-dose rule exists for 5-Amino-1MQ.
Do not double doses based on an editorial schedule; discuss interruptions with a clinician or research supervisor.
When to seek help
Any systemic reaction, severe headache, chest symptom, severe jitteriness, breathing symptom, swelling, or severe injection-site reaction.
Stop use and contact a clinician; urgent care for severe systemic symptoms.
Approved injection sites
Abdomen
Rotate sites daily and stay at least 2 inches from the navel.
Avoid: Avoid bruised, red, hard, scarred, or irritated skin.
Thigh
Rotate between abdomen and outer thigh areas.
Avoid: Avoid tender, bruised, red, or hardened skin.
Structured storage
research lyophilized vial
before reconstitution
-20 C
Editorial protocol says store dry, dark, and frozen.
research reconstituted vial
after reconstitution
2-8 C
Editorial page describes 2-4 weeks.
Not an approved label; use stricter compounder or research-protocol instructions.
Storage and handling
No licensed pharmaceutical storage standard exists for 5-Amino-1MQ research preparations. Editorial pages describe frozen lyophilized storage and refrigerated storage after reconstitution, but those instructions are not regulator-approved product labeling.
Research evidence
Published studies, labels, regulator pages, and curated protocol sources connected to this profile.
API source references
5-Amino-1MQ 10 mg vial PeptideDosages protocol
Editorial research protocol page for 5-Amino-1MQ 10 mg vial; not a prescribing label.
Open source ↗Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.